Heart, Lung and Circulation
Abstract| Volume 30, SUPPLEMENT 3, S141-S142, 2021

Trends in SGLT-2 Inhibitors Usage in Heart Failure Patients With Type 2 Diabetes Mellitus, in a South-East Queensland Hospital

      The 2018 Australian Heart Failure (HF) guidelines (October 2018) gave a strong recommendation for commencing sodium-glucose co-transporter-2 inhibitors (SGLT-2i) in HF patients with type 2 diabetes mellitus (T2DM). This was based on strong evidence demonstrating that SGLT-2i reduce major adverse cardiac events and HF hospitalisation in this patient population. Currently, the uptake of prescribing SGLT-2i for HF with T2DM is unclear.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect